文献速递泌尿生殖与妇科肿瘤放疗

立体定向体部放疗后前列腺特异性抗原动力学的多机构分析

Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-07-02

该多机构回顾性研究分析了1062例局限期前列腺癌患者单纯接受立体定向体部放疗(SBRT)后的PSA动力学。中位随访66个月,中位PSA最低值(nPSA)为0.2 ng/mL,84%患者nPSA≤0.5 ng/mL,26%出现良性PSA反弹。多因素分析显示nPSA是生化失败的显著预测因素,年龄和放疗剂量与较低反弹发生率相关。

要点

  • SBRT后中位nPSA为0.2 ng/mL,84%患者nPSA≤0.5 ng/mL。
  • 良性PSA反弹见于26%患者,中位反弹幅度0.52 ng/mL。
  • nPSA是生化失败的显著预测因素,年龄和剂量与反弹发生率相关。

核心结论

  • SBRT治疗后PSA最低值较低,较低的nPSA与生化失败发生率降低和至生化失败时间延长相关。
  • 良性PSA反弹发生于约四分之一患者,可晚至治疗后数年。

研究设计与样本

  • 多机构回顾性分析,纳入5家机构2004至2016年接受单纯SBRT的局限期前列腺癌患者。
  • 共纳入1062例患者,SBRT剂量为35至40 Gy分5次,排除PSA数据不足12个月或接受雄激素剥夺治疗者。
  • 中位随访66个月(四分位距36.4-89.9个月)。

主要发现

  • 按Phoenix标准生化失败发生率为4%。
  • 中位nPSA为0.2 ng/mL,中位至nPSA时间为40个月,84%患者nPSA≤0.5 ng/mL,54%患者nPSA≤0.2 ng/mL。
  • 良性PSA反弹见于26%患者,中位反弹幅度0.52 ng/mL(四分位距0.3-1.0 ng/mL),中位至反弹时间18.1个月(四分位距12.0-31.1个月)。
  • 多因素分析显示nPSA是生化失败的显著预测因素;年龄和放疗剂量与较低反弹发生率显著相关。
  • 联合潜类别模型显示nPSA和放疗剂量与更长的至生化失败时间显著相关。

关键数值与推荐

  • 生化失败采用Phoenix标准定义。
  • PSA反弹定义为良性反弹,中位幅度0.52 ng/mL(四分位距0.3-1.0 ng/mL),中位发生时间18.1个月(四分位距12.0-31.1个月)。

临床怎么用

  • SBRT后应预期PSA可降至很低水平,中位nPSA约0.2 ng/mL,达最低值时间可长达40个月。
  • 约四分之一患者出现良性PSA反弹,可晚至数年,需避免误判为生化失败。
  • nPSA较低与生化失败风险降低相关,可作为随访中的参考指标。

局限性

  • 本研究为回顾性分析,仅纳入接受单纯SBRT且排除雄激素剥夺治疗者,可能存在选择偏倚。
  • 需要进一步研究直接比较SBRT与其他治疗模式的PSA反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Understanding prostate-specific antigen (PSA) kinetics after radiation therapy plays a large role in the management of patients with prostate cancer (PCa). This is particularly true in establishing expectations regarding PSA nadir (nPSA) and PSA bounces, which can be disconcerting. As increasingly more patients are being treated with stereotactic body radiation therapy (SBRT) for low- and intermediate-risk PCa, it is imperative to understand the PSA response to SBRT. METHODS AND MATERIALS: PSA data from 5 institutions were retrospectively analyzed for patients with localized PCa treated definitively with SBRT alone from 2004 to 2016. Patients received 35 to 40 Gy in 5 fractions, per institutional standards. Patients who had less than 12 months of PSA data or received androgen deprivation therapy were excluded from this study. Linear and logistic multivariable analysis were performed to identify predictors of nPSA, bounce, and biochemical recurrence, and joint latent class models were developed to identify significant predictors of time to biochemical failure. RESULTS: A total of 1062 patients were included in this study. Median follow-up was 66 months (interquartile range [IQR], 36.4-89.9 months). Biochemical failure per the Phoenix criteria occurred in 4% of patients. Median nPSA was 0.2 ng/mL, median time to nPSA was 40 months, 84% of patients had an nPSA ≤0.5 ng/mL, and 54% of patients had an nPSA ≤0.2 ng/mL. On multivariable analysis, nPSA was a significant predictor of biochemical failure. Benign PSA bounce was noted in 26% of patients. The median magnitude of PSA bounce was 0.52 ng/mL (IQR, 0.3-1.0 ng/mL). Median time to PSA bounce was 18.1 months (IQR, 12.0-31.1 months). On multivariable analysis, age and radiation dose were significantly associated with a lower incidence of bounce. Joint latent class models modeling found that nPSA and radiation dose were significantly associated with longer time to biochemical failure. CONCLUSIONS: In this multi-institutional cohort of patients with long-term follow-up, we found that SBRT led to low nPSAs. In turn, lower nPSAs are associated with reduced incidence of, and longer time to, biochemical failure. Benign PSA bounces occurred in a quarter of patients, as late as several years after treatment. Further studies are needed to directly compare the PSA response of patients who receive SBRT versus other treatment modalities.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Jiang NY, Dang AT, Yuan Y, et al. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019. PMID: 31276777. doi:10.1016/j.ijrobp.2019.06.2539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。